Shayna Thomas-Jardin,Shruthy Suresh,Ariana Arce,Nicole Novaresi,Emily Stein,Lisa Thomas,Cheryl Lewis,Chul Ahn,Bret M. Evers,Maria E. Salvatierra,Wei Lu,Khaja Khan,Luisa Maris Solis Soto,Ignacio Wistuba,John D. Minna,Kathryn A. O'Donnell

Abstract:The integrated stress response (ISR) is an adaptive pathway hijacked by cancer cells to survive cellular stresses in the tumor microenvironment. ISR activation potently induces Programmed Death Ligand 1 (PD-L1), leading to suppression of anti-tumor immunity. Here we sought to uncover additional immune checkpoint proteins regulated by the ISR to elucidate mechanisms of tumor immune escape. We show that CD155 and PD-L1 are coordinately induced by the ISR, enhancing translation of both immune checkpoint proteins through bypass of inhibitory upstream open reading frames (uORFs) in their 5' UTRs. Analysis of primary human lung tumors identifies a significant correlation between PD-L1 and CD155 expression. ISR activation accelerates tumorigenesis and inhibits T cell function, effects that can be overcome by combining PD-1 blockade with the ISR inhibitor ISRIB. These studies uncover a novel mechanism by which two immune checkpoint proteins are coordinately regulated and suggest a new therapeutic strategy for lung cancer patients.

Coordinated translational control of multiple immune checkpoints by the integrated stress response pathway in lung cancer